Effectiveness of SNF and SBCC to Prevent Stunting Among Children in Afghanistan: a Quasi-experimental Study

NCT04581993 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 33100

Last updated 2023-08-16

No results posted yet for this study

Summary

Over the years, there has been some progress made in reducing stunting in Afghanistan, the prevalence remains high with half of the provinces experiencing rates above the WHO alert threshold. As part of the Country Strategic Plan (CSP), the World Food Programme (WFP) plans to implement a stunting prevention programme in collaboration with Ministry of Public Health (MoPH) through its Public Nutrition Department (PND) in selected locations with stunting rates above 45%. The programme will emphasis on appropriate nutrition support in the '1000 days' window of opportunity with special focus on proven effective nutrition interventions such appropriate breast feeding, complementary feeding, micronutrient supplementation, malnutrition treatment and prevention, WASH.

Conditions

  • Stunting
  • Malnutrition, Child

Interventions

DIETARY_SUPPLEMENT

Super Cereal - wheat soya blend with sugar

Pregnant and lactating women will received Super Cereal during pregnancy and first six months of lactation.

DIETARY_SUPPLEMENT

Lipid-based nutrient supplement-medium quantity (LNS-MQ)

Children will receive LNS during 6-23 months of age.

BEHAVIORAL

Social and behavior change communication (SBCC)

SBCC will be provided to improve care-givers knowledge, attitudes and practices related to infant and young child feeding.

Sponsors & Collaborators

  • Ministry of public Health Afghanistan

    collaborator UNKNOWN
  • United Nations World Food Programme (WFP)

    collaborator OTHER
  • The Aga Khan Foundation

    collaborator OTHER
  • Aga Khan Health Services

    collaborator OTHER
  • Aga Khan University

    lead OTHER

Principal Investigators

  • Sajid B Soofi, MBBS, FCPS · Aga Khan University

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
6 Months
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Afghanistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04581993 on ClinicalTrials.gov